In Sook Woo

Prof. Dr. In Sook Woo

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2016 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JHJi Hyung Hong
Ji Hyung Hong
KHKyung Sun Ha
Kyung Sun Ha
YJYun Hwa Jung
Yun Hwa Jung
HWHye Sung Won
Hye Sung Won
HAHo Jung An
Ho Jung An
IWIn Sook Woo
In Sook Woo
Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC. Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively. Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor-positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti-HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease. Anti-HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.

1 August 2017 in Cancer Letters
Verified
Journal Article
Closed access
IWIn Sook Woo
In Sook Woo
YJYun Hwa Jung
Yun Hwa Jung


1 April 2014 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
HKHyung Duk Kim
Hyung Duk Kim
KHKyung Sun Ha
Kyung Sun Ha
IWIn Sook Woo
In Sook Woo
YJYun Hwa Jung
Yun Hwa Jung
CHChi Wha Han
Chi Wha Han
TKTae-Jung Kim
Tae-Jung Kim
Development of tumor lysis syndrome (TLS) may occur after chemotherapy or spontaneously in bulky or rapidly growing tumors. This syndrome is frequent but preventable in patients with hematologic malignancies. TLS following therapy has been reported infrequently in various types of solid tumors. TLS associated with oxaliplatin containing chemotherapy in a solid tumor has never been reported. A 59-year-old man received 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy for metastatic colon cancer. Development of TLS occurred three days after administration of chemotherapy. Two days later, his abnormal laboratory findings were recovered with appropriate management. To the best of our knowledge, the current case is the first report on development of acute TLS following oxaliplatin containing chemotherapy in a patient with colon cancer. We also review the literature on tumor lysis syndrome in patients with colorectal cancer.

26 October 2006 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
IWIn Sook Woo
In Sook Woo
KKKyung‐Ae Kim
Kyung‐Ae Kim
HJHae‐Myung Jeon
Hae‐Myung Jeon
SHSook Hee Hong
Sook Hee Hong
SRSang Young Rho
Sang Young Rho
ICIn‐Sik Chung
In‐Sik Chung
Endostatin is the C‐terminal antiangiogenic fragment of the extracellular matrix protein collagen XVIII, and is generated by tumor‐derived proteases. The presence of serum endostatin in patients with gastric cancer has not been reported. The authors assessed the serum levels of endostatin in patients with gastric carcinoma and evaluated their association with the levels of vascular endothelial growth factor (VEGF) and the clinical outcome. A total of 107 patients with gastric cancer were included in the study. Pretherapeutic serum levels of endostatin and VEGF were measured using an ELISA, and compared with those in 23 healthy controls. The serum levels of endostatin and VEGF were higher in gastric cancer patients than in healthy controls (endostatin, 70.1 ± 16.6 vs. 52.2 ± 6.2 ng/mL [p < 0.001]; VEGF, 55.1 ± 7.6 vs. 32.1 ± 2.4 ng/mL [p < 0.001]; mean ± SD). Serum endostatin levels were significantly associated with the presence of distant metastases (r = 0.556, p < 0.001) and VEGF levels (r = 0.335, p < 0.001), but not with the depth of tumor invasion, differentiation, or regional lymph node status. A serum endostatin level above the 75th percentile of the distribution for the patients (79.2 ng/mL) was associated with a poor outcome (last follow‐up at 42 months; median survival time, 9 vs. 20 months [log‐rank, p = 0.017]; median time to progression, 5 vs. 10 months [log‐rank, p = 0.022]) in the patients with metastatic gastric cancer. The results suggest for the first time that an elevated serum level of endostatin at the diagnosis of metastatic gastric cancer could be predictive of a poor outcome.

1 January 2014 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
JLJeong Uk Lim
Jeong Uk Lim
IWIn Sook Woo
In Sook Woo
YJYun Hwa Jung
Yun Hwa Jung
JBJae Ho Byeon
Jae Ho Byeon
CPChan Kwon Park
Chan Kwon Park
HKHyo Rim Kim
Hyo Rim Kim
Lim JU, et al. Korean J Intern Med. 2014 Nov;29(6):830-833. http://dx.doi.org/10.3904/kjim.2014.29.6.830